Advertisement

Topics

Search Results for "Recall Promus Heart Stent"

16:49 EST 16th January 2017 | BioPortfolio

Matching Channels

BioMimics 3D™ Stent

Veryan has developed three dimensional (3D) stent technology based upon a helical shape that may be applied to a self-expanding stent platform. The initial objective was to investigate the presen...

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Aorfix

Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anat...

Heart Failure HF

Heart Transplantation

Matching News

Disappearing act: Nevada Heart and Vascular implants dissolving heart stent

Unlike traditional metal stent, this fully dissolving model leaves no metal behind to restrict natural vessel motion. 

New self-expanding heart stent from Biotronik proves effective in clinical trial

A new metallic heart

Japan OKs bioresorbable heart stent from Abbott

The Japanese Ministry of Health, Labor and Welfare has given Abbott approval for its Absorb bioresorbable heart stent for use -More- 

Two deaths spark recall of St. Jude heart devices

(Reuters) - St. Jude Medical Inc on Tuesday said it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. ...

BRIEF-Abbott says Japan approves its absorbable heart stent

* Abbott laboratories - japan has approved company's absorb bioresorbable heart stent Source text for Eikon: Further company coverage:

Japan approves use of Abbott’s bioresorbable heart stent

Abbott Laboratories’ new Absorb bio

Vanishing stent vs durable stent wars continue

Abbott Vascular’s Absorb bioresorbable stent that disappears into the body over time seems to be coming up short compared with the company

TCT 2016: Abbott’s bioresorbable heart stent not performing as expected

Highly anticipated research on Abbott

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement